{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283075","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.337573+00:00","generated_at":"2026-05-16T19:53:10.065045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH","bullets":["Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.","R&D expenses $7.6M (Q3) vs $4.2M; includes $7.4M IPR&D write-off from CorHepta acquisition.","Plans to initiate Phase 2b IMPROVE-PAH trial of IKT-001 in Q4 2025 (150 pts; 300/500 mg or placebo).","Appointed Timothy Pigot as Chief Commercial and Strategy Officer.","To present at Jefferies Global Healthcare Conference on Nov 17, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283075","json":"https://secwatch.observer/filing/0001193125-25-283075.json","markdown":"https://secwatch.observer/filing/0001193125-25-283075.md","text":"https://secwatch.observer/filing/0001193125-25-283075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/0001193125-25-283075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312525283075/d93377d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:53:10.065045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}